Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2610952rdf:typepubmed:Citationlld:pubmed
pubmed-article:2610952lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:2610952lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2610952lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:2610952lifeskim:mentionsumls-concept:C0086574lld:lifeskim
pubmed-article:2610952lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:2610952lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:2610952pubmed:issue6lld:pubmed
pubmed-article:2610952pubmed:dateCreated1990-3-9lld:pubmed
pubmed-article:2610952pubmed:abstractTextA long-term culture Epstein-Barr virus (EBV)-negative malignant lymphoid cell line (NAK) was established from a lymph node biopsy of a chronic lymphocytic leukemia patient. This cell line is of particular interest because it grows as an adherent cell line and depends on the presence of autologous conditioned medium for growth. After 6 months of growth in vitro, doubling time and cell cycle parameters were derived. Doubling time was 48 hours with over 45% cycling cells. Cell viability was over 90%. Expression of B-cell markers (CD19 and CD20) and surface immunoglobulin of the original tumor cell biopsy were roughly the same as in passage 14 (3 months in culture), including the expression of the original patient idiotype and IgM-lambda. Furthermore, binding of antiidiotypic antibodies was only slightly decreased at passage 14. Cytogenetic studies of chromosomal abnormalities in the primary tumor tissue and in later passages indicated similar abnormalities, with no translocations t(8;14), t(14;22), or t(2;8). However, frequent trisomies, deletions, and t(1;4) translocations were observed. Negative results for EBV nuclear antigen indicate that this cell line is an EBV-negative cell line.lld:pubmed
pubmed-article:2610952pubmed:languageenglld:pubmed
pubmed-article:2610952pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2610952pubmed:citationSubsetIMlld:pubmed
pubmed-article:2610952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2610952pubmed:statusMEDLINElld:pubmed
pubmed-article:2610952pubmed:issn0952-8172lld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:OldhamR KRKlld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:HubbardW JWJlld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:GazittYYlld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:ChangLLlld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:GuY WYWlld:pubmed
pubmed-article:2610952pubmed:authorpubmed-author:GangavalliAAlld:pubmed
pubmed-article:2610952pubmed:issnTypePrintlld:pubmed
pubmed-article:2610952pubmed:volume1lld:pubmed
pubmed-article:2610952pubmed:ownerNLMlld:pubmed
pubmed-article:2610952pubmed:authorsCompleteYlld:pubmed
pubmed-article:2610952pubmed:pagination328-33lld:pubmed
pubmed-article:2610952pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:meshHeadingpubmed-meshheading:2610952-...lld:pubmed
pubmed-article:2610952pubmed:year1989lld:pubmed
pubmed-article:2610952pubmed:articleTitleEstablishment and characterization of a malignant lymphoid cell line from a chronic lymphocytic leukemia patient.lld:pubmed
pubmed-article:2610952pubmed:affiliationBiotherapeutics Inc., Franklin, TN 37065-1676.lld:pubmed
pubmed-article:2610952pubmed:publicationTypeJournal Articlelld:pubmed